Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.
Br J Pharmacol. 2012 Apr;165(8):2721-35. doi: 10.1111/j.1476-5381.2011.01726.x.
Combination therapies are becoming increasingly important for the treatment of high blood pressure. Little is known about whether double blockade of angiotensin II (AT(1) ) receptors and angiotensin-converting enzyme (ACE) exert synergistic metabolic effects.
Spontaneously hypertensive rats were allowed to choose between palatable chocolate bars and standard chow and were simultaneously treated with the AT(1) blocker telmisartan (8 mg·kg(bw) (-1) ·day(-1) ), the ACE inhibitor ramipril (4 mg·kg(bw) (-1) ·day(-1) ) or a combination of the two (8 + 4 mg·kg(bw) (-1) ·day(-1) ) for 12 weeks.
Although food-dependent energy intake was increased by telmisartan and telmisartan + ramipril compared with ramipril or controls, body weight gain, abundance of fat and plasma leptin levels were decreased. Increased insulin levels in response to an oral glucose tolerance test were comparably attenuated by telmisartan and telmisartan + ramipril, but not by ramipril. During an insulin tolerance test, glucose utilization was equally as effectively improved by telmisartan and telmisartan + ramipril. In response to a stress test, ACTH, corticosterone and glucose increased in controls. These stress reactions were attenuated by telmisartan and telmisartan + ramipril.
The combination of telmisartan + ramipril was no more efficacious in regulating body weight and glucose homeostasis than telmisartan alone. However, telmisartan was more effective than ramipril in improving metabolic parameters and in reducing body weight. The association between the decrease in stress responses and the diminished glucose levels after stress supports our hypothesis that the ability of telmisartan, as an AT(1) receptor blocker, to alleviate stress reactions may contribute to its hypoglycaemic actions.
联合疗法在高血压治疗中变得越来越重要。对于血管紧张素 II(AT(1))受体和血管紧张素转换酶(ACE)的双重阻断是否会产生协同代谢作用,目前知之甚少。
自发性高血压大鼠可以选择美味的巧克力棒和标准食物,同时接受 AT(1)阻滞剂替米沙坦(8 mg·kg(bw)(-1)·天(-1))、ACE 抑制剂雷米普利(4 mg·kg(bw)(-1)·天(-1))或两者的组合(8 + 4 mg·kg(bw)(-1)·天(-1))治疗 12 周。
虽然与雷米普利或对照组相比,替米沙坦和替米沙坦+雷米普利增加了食物依赖的能量摄入,但体重增加、脂肪含量和血浆瘦素水平降低。口服葡萄糖耐量试验中胰岛素水平的增加被替米沙坦和替米沙坦+雷米普利相似地减弱,但雷米普利则没有。在胰岛素耐量试验中,葡萄糖利用同样被替米沙坦和替米沙坦+雷米普利有效改善。在应激试验中,对照组的 ACTH、皮质酮和葡萄糖增加。这些应激反应被替米沙坦和替米沙坦+雷米普利减弱。
替米沙坦+雷米普利联合治疗在调节体重和葡萄糖稳态方面并不比替米沙坦单独治疗更有效。然而,替米沙坦在改善代谢参数和降低体重方面比雷米普利更有效。应激反应减弱与应激后葡萄糖水平降低之间的关联支持我们的假设,即替米沙坦作为 AT(1)受体阻滞剂减轻应激反应的能力可能有助于其降血糖作用。